血清生化指标及凝血酶原时间在妊娠肝病患者检测中的意义探讨

分析血清生化指标及凝血酶原时间在妊娠肝病患者检测中的意义。方法 选择我院2023年1月-2024年1月妊娠肝病患者共120例,将其作为观察组,选择同期的120例妊娠健康产妇为对照组,对两组妊娠者进行静脉血采集,检测血清生化指标及凝血酶原时间。结果 观察组FIB水平低于对照组,APTT及PT较对照组长,P<0.05。观察组ALT、AST、GGT水平高于对照组P<0.05。结论 妊娠肝脏疾病病人和正常孕妇的血液生化指标和凝血酶原时间有显著的差别。方法 的测定对妊娠肝脏疾病的临床筛查具有一定的参考价值。采取主动的干预措施,可降低不良妊娠的发生率,提高生产安全,是一种值得推广的方法。

Liver disease in pregnancy

Liver diseases in pregnancy may be categorized into liver disorders that occur only in the setting of pregnancy and liver diseases that occur coincidentally with pregnancy. Hyperemesis gravidarum, preeclampsia/eclampsia, syndrome of hemolysis, elevated liver tests and low platelets (HELLP), acute fatty liver of pregnancy, and intrahepatic cholestasis of pregnancy are pregnancy-specific disorders that may cause elevations in liver tests and hepatic dysfunction. Chronic liver diseases, including cholestatic liver disease, autoimmune hepatitis, Wilson disease, and viral hepatitis may also be seen in pregnancy. Management of liver disease in pregnancy requires collaboration between obstetricians and gastroenterologists/hepatologists. Treatment of pregnancy-specific liver disorders usually involves delivery of the fetus and supportive care, whereas management of chronic liver disease in pregnancy is directed toward optimizing control of the liver disorder. Cirrhosis in the setting of pregnancy is less commonly observed but offers unique challenges for patients and practitioners. This article reviews the epidemiology, pathophysiology, diagnosis, and management of liver diseases seen in pregnancy.